ProMIS Neurosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

ProMIS Neurosciences şirketinin kazançları yıllık ortalama -23.6% oranında azalırken, Biotechs sektörünün kazançları yıllık 19% oranında artan oldu. Gelirler yıllık ortalama 61.8% oranında azalan oldu.

Anahtar bilgiler

-23.6%

Kazanç büyüme oranı

-1.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-61.8%
Özkaynak getirisi	n/a
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Gelir ve Gider Dağılımı

ProMIS Neurosciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:PMN Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	-12	4	0
31 Mar 24	-12	6	0
31 Dec 23	-13	6	0
30 Sep 23	-17	8	0
30 Jun 23	-20	8	0
31 Mar 23	-21	5	0
31 Dec 22	-18	6	0
30 Sep 22	-13	6	0
30 Jun 22	-8	6	0
31 Mar 22	-6	5	0
31 Dec 21	-10	4	0
30 Sep 21	-8	2	0
30 Jun 21	-8	1	0
31 Mar 21	-9	2	0
31 Dec 20	-4	2	0
30 Sep 20	-5	2	0
30 Jun 20	-5	2	0
31 Mar 20	-5	2	0
31 Dec 19	-6	2	0
30 Sep 19	-7	2	0
30 Jun 19	-8	2	0
31 Mar 19	-8	2	0
31 Dec 18	-7	2	0
30 Sep 18	-6	2	0
30 Jun 18	-5	2	0
31 Mar 18	-5	2	0
31 Dec 17	-5	2	0
30 Sep 17	-5	2	0
30 Jun 17	-4	2	0
31 Mar 17	-3	1	0
31 Dec 16	-3	1	0
30 Sep 16	-2	1	0
30 Jun 16	-2	1	0
31 Mar 16	-2	1	0
31 Dec 15	-2	1	0
30 Sep 15	-1	1	0
30 Jun 15	-2	1	0
31 Mar 15	-2	1	0
31 Dec 14	-2	1	0
30 Sep 14	-3	1	0
30 Jun 14	-2	1	0
31 Mar 14	-2	1	0
31 Dec 13	-2	1	-1

Kaliteli Kazançlar: PMN şu anda kârlı değil.

Büyüyen Kar Marjı: PMN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PMN kârlı değildir ve zararlar son 5 yılda yılda 23.6% oranında artmıştır.

Büyüme Hızlandırma: PMN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: PMN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -15% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: PMN 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

ProMIS Neurosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin